Solventum reported strong Q2 2026 results, beating expectations on the top and bottom line, and announced the planned separation of its Health Information Systems (HIS) business. The company raised full-year 2026 guidance for EPS, organic sales growth, operating margin, and free cash flow, driven by strong execution and a one-time tariff refund benefit. Management emphasized the near-completion of its 3M separation and continued momentum across all segments. Q2 organic growth was 9.5%, boosted by ~$125M of ERP advanced orders (worth ~630 bps), which will mostly reverse in Q3, resulting in a projected -3% to -4% sales growth in Q3.
Вывод BuzzbergRaising full-year EPS guidance to $7.10-$7.20Solventum reported strong Q2 2026 results, beating expectations on the top and bottom line, and announced the planned separation of its Health Information Systems (HIS) business. The company raised full-year 2026 guidance for EPS, organic sales growth, operating margin, and free cash flow, driven by strong execution and a one-time tariff refund benefit. Management emphasized the near-completion of its 3M separation and continued momentum across all segments. Q2 organic growth was 9.5%, boosted by ~$125M of ERP advanced orders (worth ~630 bps), which will mostly reverse in Q3, resulting in a projected -3% to -4% sales growth in Q3.Читать полный анализСвернуть анализ
Solventum reported strong Q2 2026 results, beating expectations on the top and bottom line, and announced the planned separation of its Health Information Systems (HIS) business. The company raised full-year 2026 guidance for EPS, organic sales growth, operating margin, and free cash flow, driven by strong execution and a one-time tariff refund benefit. Management emphasized the near-completion of its 3M separation and continued momentum across all segments. Q2 organic growth was 9.5%, boosted by ~$125M of ERP advanced orders (worth ~630 bps), which will mostly reverse in Q3, resulting in a projected -3% to -4% sales growth in Q3.
EPS of $2.55 included a $0.48 benefit from expected tariff refunds and a $0.34 contribution from advanced orders; normalized EPS was $1.73, ahead of expectations.
FY2026 guidance raised: EPS to $7.10-$7.20, organic growth to 2.5%-3% (3.5%-4% ex-SKU exits), operating margin to 22.2%-22.7%, and free cash flow to $200-$300M.
Company announced the separation of its HIS business, which is expected to be a focus area at an Investor Day in Q1 2027.
Revenue$2.209B
+10% QoQ
EPS$2.55
reported
Gross margin58.22%
reported
Op margin8.19%
reported
Что изменилось в этом квартале
01
Guidance
Raising full-year EPS guidance to $7.10-$7.20
Guidance · revenue to 2.75%
02
Portfolio
HIS separation to maximize shareholder value
Q2 organic growth was 9.5%, boosted by ~$125M of ERP advanced orders (worth ~630 bps), which will mostly reverse in Q3, resulting in a projected -3% to -4% sales growth in Q3.
03
Operational
ERP cutover near completion, reduces complexity
EPS of $2.55 included a $0.48 benefit from expected tariff refunds and a $0.34 contribution from advanced orders; normalized EPS was $1.73, ahead of expectations.
04
M&A
Acera growth exceeds 40% with high margins
FY2026 guidance raised: EPS to $7.10-$7.20, organic growth to 2.5%-3% (3.5%-4% ex-SKU exits), operating margin to 22.2%-22.7%, and free cash flow to $200-$300M.
AI, капзатраты и спрос
AI
Платформа и монетизация
Management highlighted AI as a major growth driver, particularly in the HIS business through new AI-driven autonomous coding applications and a continual stream of market-leading autonomous coding innovations. They believe HIS can capitalize on fast-moving advances in AI better if separated as an independent company or combined with a scale player.
Спрос
Заказы и конверсия
Management reported strong underlying demand, noting they are not seeing any softness in procedures or momentum in their markets. They cited under-penetration in growth drivers like IV site management, where Tegaderm CHG is used less than 20% of the time, representing over 80% of the opportunity.
Тон · Confident
Management expressed strong confidence in execution, raised guidance, and highlighted accelerating progress toward long-range plans, though they acknowledged ERP-related noise.
Альфа цепочки поставок
A1
The $125 million of ERP advanced orders in Q2 is roughly a half-quarter of inventory; customers will burn through it in Q3, and Q3 growth is expected to be -3% to -4% before rebounding to +3-4% in Q4, creating a U-shaped quarterly cadence.
“with those advanced orders reversing mostly in Q3, we're going to expect that Q3 to be in that minus three to minus 4% range.”
Solventum's Tegaderm CHG, the only FDA-cleared transparent dressing to reduce catheter-related bloodstream infections, has less than 20% penetration despite being a superior clinical solution, representing an over 80% upside opportunity in IV site management.
“Tegaderm CHG is the only transparent dressing cleared by the FDA to reduce catheter-related bloodstream infections. Studies show nearly 60% lower infection rates versus non-CHD solutions, and yet it's used less than 20% of the time.”
Solventum has received inbound interest in its Health Information Systems (HIS) business for a while, and expects a large field of interested parties now that the separation is public, with a spin-off also being considered.
“Relative to are we getting any inbound offers or any inbound approaches, we've been getting that for a while. So that's not new. Certainly now I think it's going to increase as a result of making this public”
Solventum is nearing the end of its separation from 3M, which has been a major source of complexity and cost; completing it removes risk and frees up resources.
“Let me start with the separation from 3M because we're now in the final steps. The final phases of our ERP cutover are already in motion”
… on our transformation. And as a quick reminder, our transformation has three phases, stabilize and separate the business, reposition it for profitable growth and optimize the portfolio. And importantly, as we've said from the beginning, These phases are not sequential. They're running concurrently. Different initiatives are progressing at different speeds, but all three phases continue to move forward and increasingly reinforce one another. Let me start with the separation from 3M because we're now in the final steps. The final phases of our ERP cutover are already in motion and getting to the other side of this, it's a big deal. It removes a significant amount of complexity from the business. It frees up talent and resources for innovation and margin expansion and it meaningfully improves free cash flow. Just put simply, we're very close to moving from an environment with separation distraction to full operating mode. Now let's talk portfolio optimization because we took another major step today. As we just announced, we're advancing the separation of our health information systems business with a clear objective, pursuing the path that maximizes value. And let me walk you …
Cookie
Мы используем cookie для работы сайта и аналитики. Если вы откажетесь, доступ к контенту не изменится.